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Neurofibromatosis 1 (NF1) is a relatively common, autosomal dominant, neuro-cutaneous genetic 
disorder caused by a germline mutation in the NF1 tumour suppressor gene on chromosome 17q11.1 
The disorder is associated with the development of several benign and malignant neoplasms, of 
which malignant peripheral nerve sheath tumours (MPNST) are the most common malignancy.2 The 
incidence of MPNST in patients with NF1 is more than 4000 times that of the general population.3 
MPNST associated with NF1 occur at a younger age, are multicentric and carry a worse prognosis 
than sporadic MPNST.3,4 Importantly, it is the leading cause of early death in patients with NF1.5 
Clinical features of NF1 usually develop in childhood, but MPNST is most prevalent between the age 
of 20 and 40 years.4 Currently no adult NF1 surveillance programme exists in the Western Cape 
public health system that could lead to the timely diagnosis and management of these tumours. This 
case series describes the clinico-pathologic characteristics, treatment and outcomes of four cases of 
MPNST in patients with NF1 referred to the sarcoma multidisciplinary team (SMDT) at Tygerberg 
Academic Hospital (TBAH), between 2013 and 2016.
Methods
The medical records of four patients diagnosed with NF1-associated MPNST were retrospectively 
reviewed by the first author. Data pertaining to demographics, tumour stage, histology, pertinent 
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clinical features, treatment modalities, recurrence and 
survival were captured. In addition, the histological slides of 
each patient were reviewed.
Ethical considerations
Ethics approval of conformance with the Declaration of 
Helsinki was obtained from the University of Stellenbosch 
Health Research Ethics Committee, reference number 
C16/06/008.
Cases
Clinical, histological, treatment and outcome data are 
presented in Table 1.
Patient 1
A 36-year-old male, known with NF1, presented with an 
8-month history of a rapidly enlarging soft tissue mass 
anterior to the sternum. Prior surgical history included 
excision of a large (13.7 kg) truncal neurofibroma. Examination 
revealed multiple superficial neurofibromas and café-au-lait 
(CAL) macules of his trunk, upper limbs and face. The sternal 
mass measured 10 cm × 9 cm, was fixed to the chest wall and 
was ulcerated. A mobile left sub-centimetre axillary node 
was palpated. A punch biopsy of the mass showed features of 
a pleomorphic sarcoma. Fine needle aspiration biopsies of 
the left axillary node proved to be insufficient for analysis. 
Staging computer tomography (CT) showed a large, 
fungating sternal skin tumour (5.8 cm × 7.9 cm) with irregular 
enhancement and central necrosis (Figure 1). It was 
indistinguishable from the medial aspect of the right 
pectoralis muscle, but no bone erosion was noted. Multiple 
bilateral sub-centimetre axillary nodes were present as well 
as one node in the right axilla measuring 1.6 cm in the short 
axis. There were no visceral or bony metastases. Kyphosis of 
T6-8 with vertebral fusion was also noted. He was assessed 
by the SMDT and staged as a Stage III (T2aN1M0Gx) high-
grade (HG) soft tissue sarcoma (STS). He underwent a wide 
local excision (WLE), which confirmed a 6.5 cm × 6 cm × 5 cm 
Grade 3 subcutaneous MPNST. The closest tumour-free 
margin measured 1.5 mm at depth. No axillary nodes 
were sampled. At post-operative SMDT review the node in 
the right axilla had enlarged, now measuring 2 cm × 2 cm. 
Fine needle aspiration biopsies revealed only reactive 
lymphocytes. Adjuvant external beam radiotherapy (EBRT) 
to the tumour bed was offered to decrease the risk of local 
recurrence. However, the patient did not return for EBRT and 
only presented again 2 months later with further enlargement 
FIGURE 1: Patient 1 axial contrasted computed tomography through primary 
sternal malignant peripheral nerve sheath tumour showing pathological right 
axillary node.
TABLE 1: Clinical, histological, treatment and outcome data.
Variable Patient 1 Patient 2 Patient 3 Patient 4
Gender Male Male Female Female
Age 36 37 38 33
Family history of NF1 No Yes No No
Timing of NF1 diagnosis Pre-MPNST Pre-MPNST Pre-MPNST Post-MPNST
Speciality presented to Dermatology Neurosurgery/orthopaedic surgery General surgery Urology
Primary site Chest wall Brachial plexus/supraclavicular fossa Chest wall Retroperitoneum
Radiological size (TRV × CC × AP) 5.8 cm × 7.9 cm 11 cm × 8 cm 4.2 cm × 5.6 cm × 4.7 cm 15 cm × 15 cm × 16 cm
Scoliosis Yes No No Yes
AJCC stage group (2010) 3 (T2aN1M0G3) 3 (T2bN0M0G3) 2B (T2bN0M0G2) 4 (T2bN0M1G3)
Surgery WLE Excision WLE Unresectable
Heterologous differentiation Smooth muscle Smooth muscle, angiosarcomatous Skeletal muscle Smooth muscle 
FNCLCC grade 3 3 2 3
Excision margins Negative Positive Negative N/A
Radiotherapy No Palliative CRT 30 Gray in 10 fractions, 
weekly Adriamycin
Palliative RT 8 Gray in 1 fraction
Adjuvant EBRT
60 Gray in 30 fractions
No
Chemotherapy No Palliative§ Adjuvant¶ Palliative§ 
Time to treatment† 2 m Simultaneous 4 m 2 m
Time to PD‡ 3 m 2 m N/A 2 m
OS 24 m (lost to FU) 16 m 26 m (alive with CR) 8 m 
NF1, neurofibromatosis 1; MPNST, malignant peripheral nerve sheath tumour; m, months; WLE, wide local excision; PD, progressive disease; SD, stable disease; OS, overall survival; AJCC, American 
Joint Committee on Cancer; FNCLCC, Fédération Nationale des Centres de Lutte Contre le Cancer; RT, radiotherapy; FU, follow-up; EBRT, external beam radiotherapy; CRT, chemoradiotherapy; TRV, 
transverse; CC, cranio-caudal; AP, anterior-posterior; CR, complete remission; N/A, not applicable.
†, From histological diagnosis; ‡, from first treatment; §, adriamycin q3 weekly × 6; ¶, adriamycin and ifosfamide q4 weekly × 4.
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of the right axillary node, now measuring 4 × 4 cm. He was 
referred for an axillary nodal dissection but did not attend 
the appointment. The patient was recalled, and a right 
axillary nodal dissection was performed 5 months after his 
WLE. Histological examination confirmed a metastatic 
MPNST with extra-capsular extension. The patient was 
offered adjuvant EBRT to the primary tumour bed 
followed by adjuvant chemotherapy but defaulted further 
treatment. He re-presented 16 months after his axillary 
dissection with a 3-month history of bilateral painful 
axillary masses and severe shortness of breath. Investigations 
revealed progressive disease with ulcerated axillary nodal 
recurrences, malignant pleural and pericardial effusions, 
and pleural metastases causing superior vena cava 
compression. His symptoms were palliated with a pleural tap 
and mediastinal and axillary EBRT. The patient was lost to 
follow-up 24 months from diagnosis and is presumed to have 
passed away.
Patient 2
A 37-year-old male, known with NF1, presented with a 3-year 
history of a 10 cm × 10 cm enlarging mass of the right shoulder 
with paraesthesia and motor weakness of the arm. He was 
diagnosed with NF1 at the age of 15 and was referred to 
TBAH for genetic counselling. Both his father and sister 
had NF1 and his 3-year-old son had CAL macules. Magnetic 
resonance imaging (MRI) of the chest showed an 11 cm × 8 cm 
heterogeneously enhancing mass in the right supraclavicular 
area suggestive of a MPNST arising from the brachial plexus 
and eroding the first rib (Figure 2). Deep neurofibromas were 
noted in the spinal cord at the levels of C6 and C7. The mass 
was resected in fragments that showed a HG MPNST arising 
from a plexiform neurofibroma. All resection margins were 
positive. The pathological stage was Stage III (pT2bN0M0G3). 
Post-operatively the patient had complete right-sided brachial 
plexus fallout. The patient was not referred to the SMDT for 
consideration of possible adjuvant therapy at this point. The 
patient returned 2 months post-operatively with painful 
recurrence (14 cm × 8 cm) of the supraclavicular mass as well 
as dyspnoea. Imaging showed a recurrence of the right 
supraclavicular lesion extending intrapleurally, with a right 
pleural effusion and extradural extension into the spinal canal 
but without spinal cord compromise. No visceral or 
mediastinal metastases were noted. The recurrence was 
deemed unresectable and the patient was referred to the 
SMDT for management planning. The patient received 
palliative EBRT with weekly chemotherapy. Chest CT 
2 months later showed reduction in the size of the primary 
tumour but revealed new lung metastases. The patient was 
given palliative chemotherapy. Restaging chest CT showed 
progression of the lung metastases but regression of the 
brachial plexus mass. At 15 months from diagnosis the patient 
developed significant local airway compression because of 
enlargement of the supraclavicular mass. A single fraction of 
palliative EBRT was administered and the patient demised 16 
months from MPNST diagnosis.
Patient 3
A 38-year-old female, known with NF1, was referred with an 8 
cm × 8 cm mass of the right costal margin, which had been 
slowly enlarging since her previous pregnancy 2 years before. 
She reported noting superficial neurofibromas and CAL 
macules on her trunk, face and limbs since the age of 15 but was 
only formally diagnosed with NF1 at the age of 35 (Figure 3). 
She reported marked increase in the number of lesions during 
her previous two pregnancies. A core biopsy of the chest wall 
mass showed MPNST. Staging MRI of the chest revealed a 4.2 
cm × 5.6 cm × 4.7 cm heterogeneous mass lateral to the 9th and 
10th ribs. The mass was noted to protrude into the intercostal 
space but did not cause bony erosion or peritoneal invasion. 
She underwent a WLE with the closest tumour-free margin 
being reported as 1 mm at depth. Chest CT showed no lung 
metastases. At this point she was discussed at the SMDT and 
FIGURE 2: Patient 2 gadolinium-enhanced magnetic resonance imaging of 
primary tumour. FIGURE 3: Patient 3 skin manifestations of neurofibromatosis 1.
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staged as Stage IIB (T2bN0M0G2). She received adjuvant EBRT 
to the tumour bed and adjuvant chemotherapy without 
significant complications. Clinical and radiological review at 26 
months from diagnosis showed complete remission.
Patient 4
A 33-year-old female presented 2 months post-partum with a 
large left-flank mass that became evident during the final 
month of her pregnancy. She was known with hypertension 
but was not aware of having NF1. She complained of 
abdominal pain, loss of appetite, post-prandial vomiting, 
dysuria and significant weight loss. On examination she was 
European Collaborative Oncology Group Performance Status 
2 and in a wheelchair. She had a palpable, painful left-flank 
mass crossing the midline and cutaneous stigmata of NF1, 
including CAL macules and superficial neurofibromas over 
her trunk, limbs and face. These skin lesions had been present 
since childhood and had increased in number and size after 
menarche and during her pregnancies but were asymptomatic. 
Abdominal CT showed a 15 cm × 16 cm × 15 cm retroperitoneal 
mass effacing the psoas muscle and displacing the left kidney. 
The mass extended to the left iliac wing and the abdominal 
wall muscles. No hydronephrosis or visceral, bony or nodal 
metastases were seen. A transcutaneous core biopsy of the 
mass showed a spindle cell tumour, not otherwise specified, 
and a repeat biopsy was recommended. It should be noted 
that the pathologist was not made aware of her NF1 diagnosis. 
Chest CT showed a right apical soft tissue mass in keeping 
with a lung metastasis as well as a small left pleural effusion. 
Repeat abdominal CT showed disease progression with 
an increase in the size of the tumour as well as new onset 
left hydronephrosis and extensive tumour deposits in the 
peritoneum, 12th rib and left iliac muscle. An open biopsy 
was performed and showed a HG STS most likely in keeping 
with an MPNST. She was staged as Stage IV (T2bN0M1G3) 
HG MPNST with lung metastases. She received palliative 
chemotherapy. Restaging CT abdomen after four cycles 
showed no change in the size of the tumour but increased 
internal necrosis as well as a new left pleural effusion. Despite 
this the chemotherapy provided significant symptom relief 
and improvement in performance status and she completed 
six cycles. She succumbed to progressive disease 11 weeks 
later at 8 months from diagnosis.
Discussion
Neurofibromatosis 1
Estimated birth incidences for NF1 of 1 in 2500 to 1 in 3000 
have been reported.6,7 Approximately 50% of cases are 
familial, being inherited in an autosomal dominant pattern, 
and in 50% the mutation arises de novo. The condition is 
fully penetrant, with all individuals carrying a mutation 
expressing the disorder. Clinical manifestations can however 
be variable even within families and develop with age.8 In 
our series only one of the patients reported a parent or 
sibling with NF1. This may not be a true reflection of the 
patterns of inheritance as it is quite common for patients 
attending TBAH to be unaware of their familial medical 
history. Of the 16 children born between the four patients, 
six have subsequently been assessed by the division of 
clinical genetics and only one has been diagnosed with NF1.
The clinical manifestations of NF1 most commonly affect the 
skin, skeletal and nervous systems. Table 2 details these 
TABLE 2: Clinical manifestations of neurofibromatosis 1.7,9
Organ system Clinical manifestations Complications
Skin Café-au-lait macules Disfigurement
Skin-fold freckling 
Peripheral nerves Cutaneous neurofibromas Disfigurement, tenderness, pruritus, traumatic injury, low potential for malignant 
transformation
Plexiform neurofibromas Soft tissue infiltration, bony hypertrophy, spinal cord or nerve root compression, 
potential for malignant transformation 
Central nervous system Cerebral and optic pathway gliomas Raised ICP, visual impairment, squint
Epilepsy Status epilepticus
Cerebrovasculopathy Cerebrovascular events 
Cognitive impairment Learning difficulty, behavioural problems, impaired insight into medical care
Psychological distress Depression, anxiety
Skeletal Sphenoid wing dysplasia Skull deformity, disfigurement, exophthalmos
Scoliosis Nerve root and spinal cord compression, respiratory compromise, muscle spasm, 
disfigurement
Bowing of long bones (± congenital tibial pseudo arthrosis) Fracture, disfigurement, may require amputation
Ophthalmological Lisch nodules –
Cardiovascular Vasculopathy (renal artery stenosis, coarctation of the 
aorta, pulmonary artery stenosis)
Hypertension, cardiac failure
Essential hypertension End organ damage
Congenital heart defects Cardiac failure, arrhythmias
Peripheral glomus tumours Pain
Gastrointestinal GIST Obstruction, bleeding
Endocrine Pheochromocytoma Hypertension
Growth Short stature, macrocephaly Disfigurement
Haematological Leukaemia Significant multi-system morbidity and mortality
Source: Ferner et al. and Korf
ICP, intra-cranial pressure; GIST, gastrointestinal stromal tumour.
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manifestations according to organ system along with possible 
related complications.7,9 The clinical diagnosis of NF1 is 
based on the diagnostic criteria developed by the National 
Institutes of Health Consensus Development Conference and 
published in 1988 (Box 1).10 Two or more diagnostic criteria 
need to be met to make a conclusive clinical diagnosis and 
can be used from late childhood. Nearly all patients develop 
characteristic clinical features before the age of 8 years.4
In the South African setting the diagnosis is usually 
established based on clinical manifestations, with genetic 
testing being reserved for clinically uncertain cases and 
antenatal diagnoses. This can be ascribed to the high cost of 
genetic testing resulting from the large gene size and large 
number of different known mutations and to the fact that a 
clinical diagnosis based on non-invasive evaluation usually 
can be made before serious complications occur. In our series, 
three patients were aware of their NF1 diagnosis, but only 
one had received formal genetic counselling and advice 
about possible future medical complications related to the 
condition. Importantly, none of the four patients were part of 
a follow-up programme.
Pregnancy in the NF1 patient may require specialist 
supervision because of higher rates of pregnancy-associated 
hypertension and perinatal complications including preterm 
labour, increased caesarean section rates and intrauterine 
growth restriction.11 In addition, hormonal changes because 
of pregnancy have been reported to be associated with an 
increase in the number and size of neurofibromas as was seen 
in Patients 3 and 4. This could lead to complications like 
spinal cord compression and pelvic outlet obstruction.12,13 All 
pregnant NF1 patients should receive genetic counselling as 
the risk of having a child with NF1 is 50% with each pregnancy 
and clinical manifestations can be widely variable.13
Malignant peripheral nerve sheath tumour
In the general population, MPNST is a rare disorder with a 
reported incidence of 0.001%. Patients with NF1 however 
have an estimated lifetime risk of being diagnosed with 
MPNST of 8% – 13%. Between 20% and 50% of MPNST are 
NF1-associated.14 MPNST show no gender predilection 
and typically present at an earlier age when compared with 
other STSs, which tend to predominate in patients beyond 
the sixth decade.15,16,17,18 MPNST may arise in a pre-existing 
neurofibroma or de novo in any peripheral nerve. They 
are however more likely to be associated with plexiform 
neurofibromas, particularly those associated with the 
brachial or sacral plexuses.19 NF1-associated lesions tend to 
be located on the trunk rather than the extremities as with 
non-NF1 MPNST.17 Lesions typically present as palpable, 
painless, enlarging soft tissue masses often larger than 
5 cm.15,20 Patients may also present with symptoms specific 
to the involved nerve, including pain, paraesthesia and 
motor deficits.21 The onset of new, progressive or persistent 
pain in a pre-existing neurofibroma should be thoroughly 
investigated. In this series patients were referred from 
secondary-level healthcare facilities with complaints of 
enlarging masses, local neuropathic symptoms, ulceration 
and systemic symptoms. They were referred to the divisions 
of dermatology, neurosurgery, general surgery and urology, 
respectively, which is consistent with internationally reported 
trends of diverse referral patterns. Three patients had Stage 
III or IV disease and all had tumours larger than 5 cm that 
could conceivably have been diagnosed at an earlier stage. 
The possible relationship between hormonal changes during 
pregnancy and malignant transformation of benign 
neurofibromas in NF1 patients has been explored in a small 
number of case reports and preclinical studies, but a definitive 
association has not been proven.12,13
From a diagnostic point of view MPNST is a malignancy 
arising (1) from a peripheral nerve, (2) from a pre-existing 
benign peripheral nerve sheath tumour (usually neurofibroma) 
or (3) in patients with NF1 disease.22 Outside these scenarios 
extensive immunohistochemical tests, ultra-structural studies 
and molecular testing is required to confidently distinguish 
MPNST from other STSs, because of the diverse morphology 
of these tumours. The diverse morphology can include 
heterologous differentiation, which is relatively more common 
in the setting of NF1.23,24,25 Diagnosis outside the setting of NF1 
can therefore be challenging especially on limited tissue 
samples and it is therefore imperative that communication 
between the surgeon and pathologist is maintained regarding 
the history of NF1. This can avert the need for costly repeat 
biopsies and additional immuno-histochemical and molecular 
investigation. The most widely accepted grading system for 
STSs is the French FNCLCC (Fédération Nationale des Centres 
de Lutte Contre le Cancer) system, which is three-tiered and 
based on tumour differentiation, amount of necrosis and 
mitotic activity. The system has not been proven to be of 
prognostic relevance in MPNST, with most lesions being 
regarded as HG ‘by default’ and some authors suggesting a 
two-tiered grading system that takes NF1 status into 
account.16,24,26 The pathological findings of this series are 
included in Table 1.
Management of malignant peripheral nerve 
sheath tumour
The staging and management of MPNST follows the 
guidelines for adult-type STSs and relies heavily on the 
collaboration of a multidisciplinary team of specialists from 
the time of diagnosis to ensure disease control.27 Surgical 
resection with clear margins remains the mainstay of curative 
treatment, with the addition of radiotherapy (RT) and 
chemotherapy effecting a local control advantage but not a 
BOX 1: Diagnostic criteria for neurofibromatosis 1.10
Presence of two or more of the following features:
• Six or more café-au-lait macules over 5 mm in greatest diameter in prepubertal 
individuals and over 15 mm in greatest diameter in post-pubertal individuals
• Two or more neurofibromas of any type or one plexiform neurofibroma
• Freckling in the axillary or inguinal regions
• Optic glioma
• Two or more Lisch nodules (iris hamartomas)
• A distinctive osseous lesion such as sphenoid dysplasia, thinning of long bone 
cortex causing anterolateral tibial bowing with or without pseudarthrosis
• A first-degree relative (parent, sibling or offspring) with neurofibromatosis 1 as 
defined by the above criteria
Source: National Institutes of Health
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proven survival benefit.28,29,30,31,32 Neo-adjuvant and adjuvant 
RT have also allowed for higher rates of limb salvage.30,33
Patient outcomes are summarised in Table 1. The three non-
metastatic patients all underwent WLE of their primary 
lesions by a general or orthopaedic surgeon. Despite TBAH 
having an established SMDT only one patient was discussed 
there prior to surgical intervention. All three had suboptimal 
(< 1 cm) resection margins. One patient received adjuvant 
chemotherapy and RT. The remaining two had loco-regional 
recurrence at 2 and 3 months after surgery. Three patients 
received palliative chemotherapy, one upfront and two at 
time of progression. Two patients received palliative RT at 
time of progression. In this series there was a mean 3.5-month 
delay (range 2–6) from presentation to TBAH and initiation 
of treatment for MPNST. This constitutes unacceptable delays 
in the management of an aggressive malignancy.
MPNST is associated with higher rates of local recurrence, 
distant spread and worse tumour-related survival compared 
to other STS.17 In addition to advanced stage and recurrent 
lesions, size greater than 5 cm, incomplete resection, HG and 
rhabdomyoblastic differentiation have been identified as 
poor prognostic factors.3,18,20,34 Overall survival (OS) rates of 
45% – 55% have been reported in modern series.17,34 The 
prognostic effect of NF1 on MPNST has been inconsistently 
reported, with some series reporting no effect on 
survival15,26,34,35 and others showing decreased survival 
outcomes in NF1 patients.3,16,17,20,36 A recent series reported 
5-year OS of 60% in sporadic MPNST versus 32% in NF1-
associated disease.17 However, a meta-analysis of MPNST 
case series published between 1963 and 2012 including more 
than 1800 patients showed that prognosis was significantly 
worse in patients with NF1 but that the difference became 
less significant over the last decade of the study period 
(2001–2012).34 It is unclear whether the worse prognosis in 
NF1-associated MPNST was related to tumour biology or a 
result of clinical factors such as delayed presentation with 
increased risk of systemic dissemination and larger tumours 
with ensuing subtotal resection. The apparent improvement 
in recent outcomes could possibly be ascribed to earlier 
diagnosis because of NF1 surveillance programmes and the 
availability of treatment guidelines.20,34
Recommendations for adult neurofibromatosis 1 
surveillance
Because NF1 is a complex disease with a wide variety of 
clinical manifestations, these patients present to different 
medical and surgical specialities. These may include general 
practitioners, paediatricians, neurologists, dermatologists, 
surgeons, obstetricians, geneticists and oncologists.37 Many 
individuals with NF1 lead healthy lives with only cosmetic 
concerns because of skin pigmentation and neurofibromas. 
Only a third of individuals with NF1 will ultimately have 
medical problems related to the disorder. Some of these 
problems will be mild and easily treatable and others will 
be more severe and need specialist or urgent attention. 
Therefore lifelong health surveillance is advised for specific, 
well-defined, potentially serious complications to aid early 
detection and timeous treatment.4
One of the challenges in the care of individuals with NF1 in 
South Africa is the absence of a structured surveillance 
service. Such a service would facilitate the diagnosis and 
registration of NF1 during childhood, continue to monitor 
affected individuals for complications and provide ongoing 
age-appropriate counselling about the condition, potential 
complications and the familial implications of the disease. 
Only one of the patients in the series had received prior 
genetic counselling as an adolescent, but this was not 
followed up. This lack of preventative management could be 
attributed to the mostly reactive role of the public healthcare 
system, lack of funds and the lack of communication and 
cooperation between the different levels and different 
disciplines in the public healthcare system. Without education 
and counselling, affected individuals often display delayed 
and inconsistent healthcare-seeking behaviour, which, in the 
case of an aggressive tumour like MPNST, can result in 
preventable morbidity and mortality.
The establishment and strengthening of structured surveillance 
programmes for NF1 patients in the paediatric setting is an 
essential foundation for adult NF1 care but falls outside the 
scope of this article. Those individuals who are treated for 
NF1-related complications during childhood are mostly 
retained in the system, but transition to adult care is often 
inconsistent. To our knowledge there is no formal surveillance 
protocol beyond late childhood for uncomplicated NF1 
patients in the Western Cape public health system to facilitate 
lifelong healthcare management.
In Box 2 we propose a basic surveillance strategy for 
NF1 adults over the age of 18 years in resource-limited 
settings, considering current international guidelines and 
constraints in the public healthcare services.4,7,14,38 It outlines 
ongoing surveillance that includes regular focussed clinical 
examination by a primary healthcare clinician, patient 
education regarding potential complications of NF1 and 
information on symptoms that should prompt medical 
attention. It is proposed that the surveillance programme be 
patient-driven but that the necessary support be given in the 
form of information leaflets and contact details of NF1 
BOX 2: Proposed surveillance guidelines for adult (> 18 years) neurofibromatosis 
1 patients.
• Annual physical examination and symptom enquiry by a general physician
 n Skin examination for symptomatic neurofibromas
 n Neurological and spinal exam for symptoms and signs of deep plexiform 
neurofibromas and scoliosis
 n Blood pressure measurement
• High index of suspicion and early referral of potential MPNST to tertiary referral 
service: Any new, progressive or persistent pain or rapid growth, either in 
pre-existing plexiform tumour or deep-seated locations, for example, branchial 
plexus or sciatic nerve
• Advise to avoid radiotherapy as it may increase risk of MPNST
• Patient education on inheritance patterns of NF1 and pregnancy-related 
complications
• Psycho-social and occupational support for self-esteem and cognitive problems
• Monitoring of those who have abnormalities of the central nervous system, 
skeletal system or cardiovascular system by an appropriate specialist
• Other studies (e.g. MRI) only as indicated on the basis of clinical signs or symptoms
Source: Adapted from Jett and Friedman, Ferner et al., Evans et al., Hersh
MPNST, malignant peripheral nerve sheath tumour; MRI, magnetic resonance imaging; NF1, 
neurofibromatosis 1.
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specialist clinics to ensure effective and rapid diagnosis and 
management of complications should they arise. As a direct 
result of this collaboration, the TBAH Division of Medical 
Genetics has formulated a patient-centred information leaflet 
that explains the genetic cause and inheritance patterns, 
clinical manifestations and complications of NF1 as well as 
guidelines for surveillance of children and adults.39 The 
families of three of the patients have subsequently received 
counselling and screening for NF1.
There are currently no dedicated multidisciplinary NF1 
specialist clinics in the public health sector beyond childhood. 
It is recommended that such clinics combine the expertise of 
neurologists, geneticists, ophthalmologists, endocrinologists, 
neurosurgeons, plastic surgeons, orthopaedic surgeons, 
soft tissue tumour surgeons, psychiatrists, dermatologists, 
radiologists, oncologists and pathologists.7,38 All this expertise 
co-exists in public tertiary health facilities and, although time 
and service constraints hinder them from having formal 
meetings, effective communication using technology and 
shared goals mean that ‘virtual’ NF1 clinics could be 
established without too much effort. Benefits of such a service 
would include (1) consensus diagnosis of difficult cases, 
(2) providing a contact point for expedited referral, 
diagnosis and management of complications of NF1, 
(3) multidisciplinary management of serious complications 
of NF1, (4) providing support and education for patients and 
their families and (5) overseeing public and professional 
education on NF1. The challenge lies in identifying 
champions to establish and lead such clinics in tertiary 
institutions. Until such collaborative efforts are adequately 
established, basic guidelines can be introduced in the form of 
a patient information leaflet to inform both patients and their 
primary healthcare workers about important surveillance 
activities that can reduce morbidity. A further recommendation 
is that all cases of suspected or confirmed MPNST in patients 
with NF1 be referred to an SMDT for staging and management 
before any definitive surgery is attempted.17,20
Conclusions
The prevalence of NF1 in South Africa is not well documented, 
but with a worldwide birth incidence as high as 1 in 3000 this 
condition likely affects a significant number of the population. 
Patients are usually diagnosed in childhood, but close follow-
up does not continue into adulthood, when the risk of 
complications persists and the risk of MPNST in particular is 
at its highest. MPNST is a rare but aggressive malignancy 
with poor survival outcomes, particularly in NF1 patients. In 
this series the patients presented with advanced, often 
unresectable lesions for which single modality therapy was 
not curative. There is currently no surveillance programme 
for adult NF1 patients in the Western Cape public health 
system. The combination of centralised multidisciplinary 
adult NF1 clinics and a patient-driven health surveillance 
guideline as outlined here could lead to early diagnosis and 
treatment of MPNST and other complications in patients 
with NF1 in resource-constrained healthcare systems.
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